Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932126 · ClinicalTrials.gov registry record · Phase 1
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00932126 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 35 participants.
The verdict
NCT00932126, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells.
Interventions
- DRUG PF-03758309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932126
The ClinicalTrials.gov registry entry for NCT00932126 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-03758309 is the first listed.
NCT00932126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932126 about?
NCT00932126 is a clinical study titled "This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors". This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment an...
What is the current status of trial NCT00932126?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00932126?
The interventions under investigation include: PF-03758309 (DRUG).
Who is sponsoring clinical trial NCT00932126?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.